These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Robak T; Lech-Maranda E; Robak P Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624 [TBL] [Abstract][Full Text] [Related]
23. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187 [TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Tobinai K Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934 [TBL] [Abstract][Full Text] [Related]
25. Rituximab therapy for indolent non-Hodgkin's lymphoma. Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586 [TBL] [Abstract][Full Text] [Related]
26. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W; Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739 [TBL] [Abstract][Full Text] [Related]
27. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469 [TBL] [Abstract][Full Text] [Related]
28. Diffuse aggressive lymphoma. Fisher RI; Miller TP; O'Connor OA Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685 [TBL] [Abstract][Full Text] [Related]
29. [Rituximab]. Okamoto R; Maeda Y; Sasaki T Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262 [TBL] [Abstract][Full Text] [Related]
30. Clinical use of rituximab in haematological malignancies. Avivi I; Robinson S; Goldstone A Br J Cancer; 2003 Oct; 89(8):1389-94. PubMed ID: 14562003 [TBL] [Abstract][Full Text] [Related]
31. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003 [TBL] [Abstract][Full Text] [Related]